Eli Lilly and Co. (NYSE:LLY) – Stock analysts at Leerink Swann lowered their FY2016 earnings estimates for shares of Eli Lilly and in a report issued on Wednesday. Leerink Swann analyst S. Fernandez now anticipates that the firm will post earnings per share of $3.48 for the year, down from their prior forecast of $3.57. Leerink Swann currently has a “Outperform” rating and a $92.00 price target on the stock. Leerink Swann also issued estimates for Eli Lilly and’s Q4 2016 earnings at $0.92 EPS, FY2017 earnings at $3.99 EPS and FY2018 earnings at $4.17 EPS.
A number of other analysts have also weighed in on the stock. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $384.00 price target on shares of Eli Lilly and in a research note on Saturday. Morgan Stanley set a $73.00 price target on shares of Eli Lilly and and gave the stock a “hold” rating in a research note on Thursday. Atlantic Securities downgraded shares of Eli Lilly and from an “overweight” rating to a “neutral” rating in a report on Friday. BMO Capital Markets downgraded shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $91.00 to $64.00 in a report on Wednesday, November 23rd. Finally, Citigroup Inc. reiterated a “buy” rating on shares of Eli Lilly and in a report on Tuesday, November 8th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $108.34.
Eli Lilly and (NYSE:LLY) opened at 69.12 on Monday. Eli Lilly and has a one year low of $64.18 and a one year high of $88.16. The firm has a market cap of $73.11 billion, a price-to-earnings ratio of 30.07 and a beta of 0.28. The firm has a 50 day moving average of $76.69 and a 200-day moving average of $77.92.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.96 by $0.08. The company earned $5.19 billion during the quarter, compared to analyst estimates of $4.23 billion. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.89 EPS.
Several hedge funds have recently bought and sold shares of LLY. Iowa State Bank purchased a new stake in Eli Lilly and during the second quarter valued at about $104,000. PineBridge Investments L.P. increased its stake in Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock valued at $108,000 after buying an additional 920 shares in the last quarter. Tradewinds Capital Management LLC increased its stake in Eli Lilly and by 22.3% in the third quarter. Tradewinds Capital Management LLC now owns 1,345 shares of the company’s stock valued at $108,000 after buying an additional 245 shares in the last quarter. Integrated Wealth Management increased its stake in Eli Lilly and by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock valued at $112,000 after buying an additional 50 shares in the last quarter. Finally, Financial Architects Inc increased its stake in Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock valued at $114,000 after buying an additional 61 shares in the last quarter. 75.11% of the stock is owned by institutional investors and hedge funds.
In related news, insider Maria A. Crowe sold 2,248 shares of the company’s stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the sale, the insider now directly owns 94,319 shares of the company’s stock, valued at approximately $7,674,737.03. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.20% of the company’s stock.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 9th. Investors of record on Tuesday, November 15th will be issued a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 2.95%. The ex-dividend date of this dividend is Thursday, November 10th. Eli Lilly and’s dividend payout ratio is currently 88.70%.
Eli Lilly and Company Profile